199 related articles for article (PubMed ID: 16564942)
1. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
2. The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis.
Zhang S; Ouyang M; Liu L
Chronic Illn; 2024 Jun; 20(2):221-232. PubMed ID: 37282508
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitors and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: Results from the Japan Dialysis Outcomes and Practice Patterns Study.
Nakashima A; Miyawaki Y; Komaba H; Kurita N; Onishi Y; Yokoo T; Fukagawa M
Am J Nephrol; 2024; 55(2):165-174. PubMed ID: 37935135
[TBL] [Abstract][Full Text] [Related]
4. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Pergola PE; Devalaraja M; Fishbane S; Chonchol M; Mathur VS; Smith MT; Lo L; Herzog K; Kakkar R; Davidson MH
J Am Soc Nephrol; 2021 Jan; 32(1):211-222. PubMed ID: 33272965
[TBL] [Abstract][Full Text] [Related]
5. Implications of a reduction in the hemoglobin target in erythropoiesis-stimulating agent-treated hemodialysis patients.
Nguyen TV; Goldfarb DS
Nephron Extra; 2011 Jan; 1(1):212-6. PubMed ID: 22470394
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE).
Pergola PE; Davidson M; Jensen C; Mohseni Zonoozi AA; Raj DS; Andreas Schytz P; Tuttle KR; Perkovic V
J Am Soc Nephrol; 2024 Jan; 35(1):74-84. PubMed ID: 38088558
[TBL] [Abstract][Full Text] [Related]
7. Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland.
Mathieu CM; Teta D; Lötscher N; Golshayan D; Gabutti L; Kiss D; Martin PY; Burnier M
BMC Nephrol; 2008 Dec; 9():16. PubMed ID: 19077225
[TBL] [Abstract][Full Text] [Related]
8. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.
Dimitrijevic ZM; Cvetkovic TP; Djordjevic VM; Pavlovic DD; Stefanovic NZ; Stojanovic IR; Paunovic GJ; Velickovic-Radovanovic RM
Int J Med Sci; 2012; 9(9):808-15. PubMed ID: 23136545
[TBL] [Abstract][Full Text] [Related]
9. Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS.
Akizawa T; Pisoni RL; Akiba T; Saito A; Fukuhara S; Asano Y; Hasegawa T; Port FK; Kurokawa K
Nephrol Dial Transplant; 2008 Nov; 23(11):3643-53. PubMed ID: 18577535
[TBL] [Abstract][Full Text] [Related]
10. Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study.
Karaboyas A; Morgenstern H; Pisoni RL; Zee J; Vanholder R; Jacobson SH; Inaba M; Loram LC; Port FK; Robinson BM
Nephrol Dial Transplant; 2018 Dec; 33(12):2234-2244. PubMed ID: 30010940
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the hemoglobin variability in non-chronic kidney disease or end-stage renal disease participants and patients with CKD and ESRD.
Plappert C; Müller HJ; Haubitz M; Höcker R; Weißer H; Benöhr P
Clin Nephrol; 2024 Apr; 101(4):171-180. PubMed ID: 38329918
[TBL] [Abstract][Full Text] [Related]
12. Ergocalciferol treatment does Not improve erythropoietin utilization and hospitalization rate in hemodialysis patients.
Agarwal G; Hirachan P; Gelfond J; Fanti P; Hura C; Bansal S
BMC Nephrol; 2016 Oct; 17(1):144. PubMed ID: 27717322
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.
Kuo KL; Hung SC; Wei YH; Tarng DC
J Am Soc Nephrol; 2008 Sep; 19(9):1817-26. PubMed ID: 18495964
[TBL] [Abstract][Full Text] [Related]
14. Long-term L-carnitine administration reduces erythropoietin resistance in chronic hemodialysis patients with thalassemia minor.
Di Iorio BR; Guastaferro P; Cillo N; Cucciniello E; Bellizzi V
Drug Target Insights; 2007; 2():1-7. PubMed ID: 21901057
[TBL] [Abstract][Full Text] [Related]
15. Effect of peritoneal dialysis versus hemodialysis on renal anemia in renal in end-stage disease patients: a meta-analysis.
Wang WN; Zhang WL; Sun T; Ma FZ; Su S; Xu ZG
Ren Fail; 2017 Nov; 39(1):59-66. PubMed ID: 27852131
[TBL] [Abstract][Full Text] [Related]
16. Iron indices mediate but not modify association of parathyroid hormone with erythropoietin resistance in hemodialysis patients.
Li X; Zhu L; Wang Y; Wang Y; Wu B; Gan L; Zuo L
Blood Purif; 2024 May; ():. PubMed ID: 38710167
[TBL] [Abstract][Full Text] [Related]
17. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy.
Shimamatsu K; Inamasu H
Curr Ther Res Clin Exp; 2013 Jun; 74():5-8. PubMed ID: 24384988
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Omicron variant of coronavirus disease 2019 on anaemia treatment for patients undergoing peritoneal dialysis.
Yang Q; Fang X; Ren X; Pan Y; Wang M; Ding J
Nephrology (Carlton); 2024 Apr; 29(4):222-229. PubMed ID: 38382901
[TBL] [Abstract][Full Text] [Related]
19. Trends in anemia management in US hemodialysis patients 2004-2010.
Miskulin DC; Zhou J; Tangri N; Bandeen-Roche K; Cook C; Ephraim PL; Crews DC; Scialla JJ; Sozio SM; Shafi T; Jaar BG; Boulware LE;
BMC Nephrol; 2013 Dec; 14():264. PubMed ID: 24289058
[TBL] [Abstract][Full Text] [Related]
20. Copper deficiency anemia due to zinc supplementation in a chronic hemodialysis patient.
Watanabe T; Yonemoto S; Ikeda Y; Kawaguchi K; Tsukamoto T
CEN Case Rep; 2024 Mar; ():. PubMed ID: 38520630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
